300463 Stock Overview
Engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Maccura Biotechnology Co.Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥13.20 |
| 52 Week High | CN¥17.31 |
| 52 Week Low | CN¥9.90 |
| Beta | 0.38 |
| 1 Month Change | -7.04% |
| 3 Month Change | -9.53% |
| 1 Year Change | -12.06% |
| 3 Year Change | -55.45% |
| 5 Year Change | -55.10% |
| Change since IPO | -1.64% |
Recent News & Updates
Does Maccura BiotechnologyLtd (SZSE:300463) Have A Healthy Balance Sheet?
Dec 12
Even With A 38% Surge, Cautious Investors Are Not Rewarding Maccura Biotechnology Co.Ltd's (SZSE:300463) Performance Completely
Oct 08Recent updates
Does Maccura BiotechnologyLtd (SZSE:300463) Have A Healthy Balance Sheet?
Dec 12Even With A 38% Surge, Cautious Investors Are Not Rewarding Maccura Biotechnology Co.Ltd's (SZSE:300463) Performance Completely
Oct 08Is Maccura BiotechnologyLtd (SZSE:300463) Using Too Much Debt?
Aug 01Many Still Looking Away From Maccura Biotechnology Co.Ltd (SZSE:300463)
May 28Some Investors May Be Willing To Look Past Maccura BiotechnologyLtd's (SZSE:300463) Soft Earnings
May 01Shareholder Returns
| 300463 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | -3.6% | -2.0% | 1.0% |
| 1Y | -12.1% | -21.5% | 8.2% |
Return vs Industry: 300463 exceeded the CN Life Sciences industry which returned -21.5% over the past year.
Return vs Market: 300463 underperformed the CN Market which returned 8.2% over the past year.
Price Volatility
| 300463 volatility | |
|---|---|
| 300463 Average Weekly Movement | 5.8% |
| Life Sciences Industry Average Movement | 9.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 300463 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300463's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,675 | Wu Mingjian | www.maccura.com |
Maccura Biotechnology Co Ltd engages in the research, development, manufacture, and sale of IVD products and related services in China and internationally. The company offers immunoassay products, such as chemiluminescence analyzers and reagents; clinical chemistry reagents for hepatic function, glycometabolism, iron and other, renal function, coagulation, special protein, cardiac, and lipids; and clinical laboratory products, such as automatic hematology, and automatic and semi-automatic coagulation analyzers.
Maccura Biotechnology Co.Ltd Fundamentals Summary
| 300463 fundamental statistics | |
|---|---|
| Market cap | CN¥8.22b |
| Earnings (TTM) | CN¥325.31m |
| Revenue (TTM) | CN¥2.73b |
24.6x
P/E Ratio2.9x
P/S RatioIs 300463 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300463 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.73b |
| Cost of Revenue | CN¥1.26b |
| Gross Profit | CN¥1.46b |
| Other Expenses | CN¥1.14b |
| Earnings | CN¥325.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 53.64% |
| Net Profit Margin | 11.92% |
| Debt/Equity Ratio | 11.2% |
How did 300463 perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield29%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 08:47 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Maccura Biotechnology Co.Ltd is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Pei Hui Tang | Chasing Securities |
| Pei Cheng | China Galaxy Securities Co., Ltd. |